183 related articles for article (PubMed ID: 27632557)
1. Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Täubel J; Ferber G; Fernandes S; Lorch U; Santamaría E; Izquierdo I
PLoS One; 2016; 11(9):e0163020. PubMed ID: 27632557
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
3. Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
González-Núñez V; Bachert C; Mullol J
Expert Opin Drug Saf; 2016 Oct; 15(10):1439-48. PubMed ID: 27500993
[TBL] [Abstract][Full Text] [Related]
4. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Solans A; Carbó ML; Peña J; Nadal T; Izquierdo I; Merlos M
Clin Ther; 2007 May; 29(5):900-908. PubMed ID: 17697908
[TBL] [Abstract][Full Text] [Related]
5. Rupatadine for the treatment of urticaria.
Nettis E; Delle Donne P; Di Leo E; Calogiuri GF; Ferrannini A; Vacca A
Expert Opin Pharmacother; 2013 Sep; 14(13):1807-13. PubMed ID: 23806068
[TBL] [Abstract][Full Text] [Related]
6. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria.
Metz M; Scholz E; Ferrán M; Izquierdo I; Giménez-Arnau A; Maurer M
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):86-92. PubMed ID: 20143651
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
Compalati E; Canonica GW
Curr Med Res Opin; 2013 Nov; 29(11):1539-51. PubMed ID: 23826741
[TBL] [Abstract][Full Text] [Related]
8. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Izquierdo I; Merlos M; García-Rafanell J
Drugs Today (Barc); 2003 Jun; 39(6):451-68. PubMed ID: 12944997
[TBL] [Abstract][Full Text] [Related]
9. Rupatadine in allergic rhinitis and chronic urticaria.
Mullol J; Bousquet J; Bachert C; Canonica WG; Gimenez-Arnau A; Kowalski ML; Martí-Guadaño E; Maurer M; Picado C; Scadding G; Van Cauwenberge P
Allergy; 2008 Apr; 63 Suppl 87():5-28. PubMed ID: 18339040
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Okubo K; Suzuki T; Tanaka A; Aoki H
Allergol Int; 2019 Apr; 68(2):207-215. PubMed ID: 30391169
[TBL] [Abstract][Full Text] [Related]
11. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.
Martínez-Cócera C; De Molina M; Martí-Guadaño E; Pola J; Conde J; Borja J; Pérez I; Arnaiz E; Izquierdo I;
J Investig Allergol Clin Immunol; 2005; 15(1):22-9. PubMed ID: 15864879
[TBL] [Abstract][Full Text] [Related]
12. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.
García-Gea C; Ballester MR; Martínez J; Antonijoan RM; Donado E; Izquierdo I; Barbanoj MJ
Br J Clin Pharmacol; 2010 Jun; 69(6):663-74. PubMed ID: 20565458
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments-Comparison With the Previous White Caucasian Thorough QT Study.
Täubel J; Ferber G; Fernandes S; Santamaría E; Izquierdo I
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):67-76. PubMed ID: 28763575
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Hide M; Suzuki T; Tanaka A; Aoki H
Allergol Int; 2019 Jan; 68(1):59-67. PubMed ID: 30029967
[TBL] [Abstract][Full Text] [Related]
16. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Potter P; Maspero JF; Vermeulen J; Barkai L; Németh I; Baillieau RA; Garde JM; Giralt J; Doménech A; Izquierdo I; Nieto A
Pediatr Allergy Immunol; 2013 Mar; 24(2):144-50. PubMed ID: 23384091
[TBL] [Abstract][Full Text] [Related]
17. Rupatadine: a review of its use in the management of allergic disorders.
Keam SJ; Plosker GL
Drugs; 2007; 67(3):457-74. PubMed ID: 17335300
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Saint-Martin F; Dumur JP; Pérez I; Izquierdo I;
J Investig Allergol Clin Immunol; 2004; 14(1):34-40. PubMed ID: 15160440
[TBL] [Abstract][Full Text] [Related]
19. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study.
Dubertret L; Zalupca L; Cristodoulo T; Benea V; Medina I; Fantin S; Lahfa M; Pérez I; Izquierdo I; Arnaiz E
Eur J Dermatol; 2007; 17(3):223-8. PubMed ID: 17478385
[TBL] [Abstract][Full Text] [Related]
20. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.
Stuebner P; Horak F; Zieglmayer R; Arnáiz E; Leuratti C; Pérez I; Izquierdo I
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):37-44. PubMed ID: 16440531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
